Latest On Aimmune Therapeutics, Inc (AIMT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2020-11-01 16:54 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-10-15 19:30 EST | Insider Trade | des Produits Nestle S.A. Societe has indirectly acquired of 10,681,704 shares. | Buy | |
| 2020-10-15 19:30 EST | Insider Trade | des Produits Nestle S.A. Societe has indirectly acquired of 43,435,583 shares. | Buy | |
| 2020-10-15 08:03 EST | Analyst Rating | The Analyst Target Price has decreased from $33.32 to $31.28. | Sell | |
| 2020-10-14 16:31 EST | Insider Trade | KATHRYN E FALBERG has directly disposed of 7,840 shares and currently holds 0 shares. | Sell | |
About Aimmune Therapeutics, Inc (AIMT):
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeu read more...tics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California. As of October 9, 2020, Aimmune Therapeutics, Inc. operates as a subsidiary of Société des Produits Nestlé S.A.
General
- Name Aimmune Therapeutics, Inc
- Symbol AIMT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 339
- Fiscal Year EndDecember
- IPO Date2015-08-06
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.aimmune.com
Valuation
- Price/Sales (Trailing 12 Mt.) 3832.47
- Price/Book (Most Recent Quarter) 12.55
- Enterprise Value Revenue 3628.88
Financials
- Most Recent Quarter 2020-06-30
- Next Quarter EPS Estimate -$1.05
- Operating Margin -49193%
- Return on Assets -53%
- Revenue 575000
- Earnings Per Share -$3.73
- Revenue Per Share $0.01
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 2.26 billion
- EBITDA -227014000
- PEG Ratio 0.16
- Analyst Target Price $31.28
- Book Value Per Share $2.75
Share Statistics
- Shares Outstanding 65.45 million
- Shares Float 49.01 million
- % Held by Insiders 2086%
- % Held by Institutions 82.85%
- Shares Short 4.18 million
- Shares Short Prior Month 6.74 million
- Short Ratio 0.99
- Short % of Float 9%
- Short % of Shares Outstanding 6%
Technicals
- Beta 1.74
- 52 Week High $37
- 52 Week Low $10.09
- 50 Day Moving Average 34.42
- 200 Day Moving Average 20.82
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Aimmune Therapeutics, Inc (AIMT) Dividend Calendar:
Aimmune Therapeutics, Inc (AIMT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Aimmune Therapeutics, Inc (AIMT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Aimmune Therapeutics, Inc (AIMT) Chart:
Aimmune Therapeutics, Inc (AIMT) News:
Below you will find a list of latest news for Aimmune Therapeutics, Inc (AIMT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Aimmune Therapeutics, Inc (AIMT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Aimmune Therapeutics, Inc (AIMT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-23 | 15-12B (Securities registration termination [Section 12(b)]) | |
| 2020-10-19 | 8-K (Current report) | |
| 2020-10-15 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-14 | EFFECT (Notice of Effectiveness) | |
| 2020-10-14 | EFFECT (Notice of Effectiveness) | |
| 2020-10-13 | SC 13E3/A (Going private transaction by certain issuers) | |
| 2020-10-13 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-10-13 | SC 14D9/A (Solicitation, recommendation statements) | |
Aimmune Therapeutics, Inc (AIMT) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aimmune Therapeutics, Inc (AIMT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2086%
Institutional Ownership: 8285%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-13 | Andrew Oxtoby | Chief Commercial Officer | Sell | 20,250.00 | 34.50 | 698,625.00 | 0.00 | |
| 2020-10-13 | BRETT K HAUMANN | Director | Sell | 13,313.00 | 34.50 | 459,298.50 | 0.00 | |
| 2020-10-13 | DANIEL C MD ADELMAN | Chief Medical Officer | Sell | 22,343.00 | 34.50 | 770,833.50 | 0.00 | |
| 2020-10-13 | Douglas T. Sheehy | Officer | Sell | 36,875.00 | 34.50 | 1,272,187.50 | 0.00 | |
| 2020-10-13 | ERIC BJERKHOLT | Chief Financial Officer | Sell | 23,905.00 | 34.50 | 824,722.50 | 0.00 | |
| 2020-10-13 | Gregory Behar | Director | Sell | 7,840.00 | 34.50 | 270,480.00 | 0.00 | |
| 2020-10-13 | Jayson Donald Alexander Dallas | President and CEO | Sell | 89,250.00 | 34.50 | 3,079,125.00 | 0.00 | |
| 2020-10-13 | KATHRYN E FALBERG | Director | Sell | 7,840.00 | 34.50 | 270,480.00 | 0.00 | |
| 2020-10-13 | MARK MCDADE | Director | Sell | 7,840.00 | 34.50 | 270,480.00 | 0.00 | |
| 2020-10-13 | Mark T Iwicki | Director | Sell | 7,840.00 | 34.50 | 270,480.00 | 0.00 | |
| 2020-10-13 | PATRICK G ENRIGHT | Director | Sell | 7,840.00 | 34.50 | 270,480.00 | 0.00 | |
| 2020-10-13 | Stacey Denenberg Seltzer | Director | Sell | 7,840.00 | 34.50 | 270,480.00 | 0.00 | |
| 2020-10-13 | des Produits Nestle S.A. Societe | 10% Share Holder | Buy | 10,681,704.00 | 34.50 | 368,518,788.00 | 23,408,817.00 | |
| 2020-10-13 | des Produits Nestle S.A. Societe | 10% Share Holder | Buy | 43,435,583.00 | 34.50 | 1,498,527,613.50 | 43,435,583.00 | |
| 2020-10-05 | ERIC BJERKHOLT | Chief Financial Officer | Buy | 5,200.00 | 19.44 | 101,088.00 | 49,841.00 | |
| 2020-10-05 | Douglas T. Sheehy | Officer | Buy | 30,888.00 | 12.95 | 399,999.60 | 85,426.00 | |
| 2020-10-02 | DANIEL C MD ADELMAN | Chief Medical Officer | Buy | 34,932.00 | 11.45 | 399,971.40 | 63,807.00 | |
| 2020-05-27 | Gregory Behar | Director | Buy | 7,840.00 | 18,032.00 | | ||
| 2020-05-27 | Stacey Denenberg Seltzer | Director | Buy | 7,840.00 | 18,061.00 | | ||
| 2020-05-27 | BRETT K HAUMANN | Director | Buy | 13,313.00 | 19,563.00 | |